Claims for Patent: 9,968,570

Summary for Patent: 9,968,570

Title:	Compositions and methods for treating cancer
Abstract:	The present invention provides, in part, compositions and methods for treating cancer using a combination of C6-ceramide and other anti-cancer agents in certain vesicles.
Inventor(s):	Wanebo; Harold J. (Bristol, RI)
Assignee:	Chemo-Enhanced LLC (Woonsocket, RI)
Application Number:	14/760,510
Patent Claims:	1. A method for treating pancreatic cancer comprising the step of: contacting a pancreatic cancer cell with an effective amount of a composition consisting essentially of (a) C6-ceramide; (b) an anti-cancer agent; and (c) a lipid, wherein the lipid consists essentially of two or more of 1,2-dipalmitoyl-sn-glycero-3-galloyl, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000], and 1,2-dioleoyl-sn-glycero-3-phosphocholine, thereby treating pancreatic cancer, wherein the anti-cancer agent is selected from the group consisting of paclitaxel, gemcitabine, oxaliplatin, cisplatin, cetuximab, panitumumab, erlotinib, daunorubicin, doxorubicin, cytosine arabinoside, and suramin. 2. The method of claim 1, wherein the cell is present in a subject in vivo; and the subject is a mammal. 3. The method of claim 2, wherein the subject is a human. 4. The method of claim 1, wherein the cell is comprised within a pancreatic tumor. 5. The method of claim 1, wherein the pancreatic cancer is pancreatic adenocarcinoma. 6. The method of claim 1, wherein the pancreatic cancer cell has an activating KRAS mutation. 7. The method of claim 6, wherein the activating KRAS mutations is a human KRAS polypeptide having a mutation selected from the group consisting of G12C, G12A, G12D, G12R, G12S, G12V, G13C, and G13D. 8. The method of claim 1, wherein the composition consists essentially of (a) C6-ceramide; (b) the anti-cancer agent; and (c) a lipid consisting essentially of 1,2-dipalmitoyl-sn-glycero-3-galloyl and 1,2-dioleoyl-sn-glycero-3-phosphocholine. 9. The method of claim 1, wherein the composition consists essentially of (a) C6-ceramide; (b) the anti-cancer agent; and (c) a lipid consisting essentially of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] and 1,2-dioleoyl-sn-glycero-3-phosphocholine. 10. The method of claim 1, wherein the weight ratio of (a):(b) is from about 2:1 to about 1:40. 11. The method of claim 1, wherein the anti-cancer agent comprises paclitaxel. 12. The method of claim 1, wherein the anti-cancer agent comprises gemcitabine. 13. The method of claim 1, wherein the anti-cancer agent comprises cetuximab. 14. The method of claim 1, wherein the treatment of cancer is determined by analyzing at least one condition caused by contacting the cell with the composition relative to the state of the condition in the absence of contacting the cell with the composition, wherein the at least one condition is selected from the group consisting of increased apoptosis, decreased mean rate of tumor development (MRTD), decreased mean tumor volume (MTV), decreasing mean tumor size (MTS), increasing mean body weight (MBW), increased mean survival time (MST), increased survival until mortality, pathological complete response, clinical complete remission, clinical partial remission, clinical stable disease, recurrence-free survival, metastasis free survival, and disease free survival. 15. The method of claim 14, wherein the condition is affected synergistically with respect to contacting the cell with the composition relative to the condition affected by contacting the cell with (a) alone, (b) alone, (c) alone, (a) and (b) together, (a) and (c) together, or (b) and (c) together. 16. The method of claim 1, wherein the anti-cancer agent comprises 5-fluorouracil and oxaliplatin. 17. The method of claim 1, wherein the anti-cancer agent comprises 5-fluorouracil, oxaliplatin, and cetuximab. 18. The method of claim 1, wherein the anti-cancer agent comprises cisplatin. 19. The method of claim 1, wherein the anti-cancer agent comprises oxaliplatin. 20. The method of claim 1, wherein the anti-cancer agent comprises doxorubicin. 21. The method of claim 1, wherein the anti-cancer agent is paclitaxel, gemcitabine or cisplatin.

Details for Patent 9,968,570

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2033-01-14
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2033-01-14
Amgen, Inc.	VECTIBIX	panitumumab	Injection	125147	09/27/2006		2033-01-14